Exicure Announces $115M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Exicure, Inc.® (NASDAQ:XCUR), a pioneer in gene regulatory drugs utilizing spherical nucleic acid (SNA™) technology, today announced that it has entered into a definitive agreement with several institutional
34 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Exicure, Inc. (NASDAQ: XCUR) rose 41.8% to $0.3830. Exicure’s Audit Committee recently concluded that Grant Corbett misreported raw data from certain R&D experiments related to XCUR-FXN preclinical program.
20 Stocks Moving in Tuesday’s Pre-Market Session
Gainers
MIND Technology, Inc. (NASDAQ: MIND) rose 37.2% to $1.88 in pre-market trading after the company reported it entered into a Cooperative Research and Development Agreement with the United States Navy's Naval Surface Warfare Center, Panama City Division.
Exicure Stock Plunges After Results Of Internal Probe, Management Shakeup, Layoffs
Exicure Inc's (NASDAQ: XCUR) Audit Committee concluded that Grant Corbett
Exicure Late Friday Reported Results Of Internal Probe, Implementation Of Strategic Measures To Reduce Cash Burn, Prioritize Pipeline Focus
– Exicure will reduce its workforce by approximately 50%, along with the implementation of other cost-cutting measures –
– Company to wind down immuno-oncology program cavrotolimod (AST-008) and
